ArriVent Biopharma, Inc. (AVBP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$30.95-0.26%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AVBP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue global pivotal Phase 3 studies for firmonertinib in first-line EGFR exon 20 insertion and PACC mutant NSCLC with topline data expected in 2026.
Stated as a priority in 2 of last 2 quarters. Management expects topline Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC in 2H 2026 and continues enrollment in the ALPACCA Phase 3 study for PACC mutations. The company reported a net loss of $93.2 million for the first half of 2026 and held $373.1 million in cash and investments as of June 30, 2026, expected to fund operations into 2028. The trajectory shows continued clinical advancement aligned with stated goals.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026”
“Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026”
Progress clinical development of ADC candidates ARR-217 in gastrointestinal cancers and ARR-002 in ovarian and endometrial cancers with dosing milestones in 2026.
Stated as a priority in 2 of last 2 quarters. Management advanced ARR-217 into Phase 1b dose optimization and planned dosing of the first patient with ARR-002 in Q3 2026. R&D expenses totaled $80.0 million for the first half of 2026, reflecting ongoing investment in these programs. The trajectory shows active clinical progression consistent with stated plans.
“Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC expected Q3 2026”
“ArriVent received FDA IND clearance for ARR-217 and dosed its first patient in March 2026”
License ARR-002 to Shanghai Allist Pharmaceuticals for development and commercialization in Greater China while retaining other rights.
Newly stated in 2026-Q2. Management announced a strategic licensing agreement granting Shanghai Allist Pharmaceuticals exclusive rights to develop and commercialize ARR-002 in Greater China. This expands the commercial footprint for ARR-002. No direct financial impact reported yet, so trajectory is early stage.
“Entered into an exclusive licensing agreement with Shanghai Allist Pharmaceuticals Co., Ltd. for ARR-002 in Greater China”
Focus on enrolling the first patient in the ALPACCA Phase 3 study for firmonertinib monotherapy in EGFR PACC mutant NSCLC.
Over the trailing year it converted 0.98x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
6 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.